Human immunodeficiency virus type 1 protease inhibitors.
Human immunodeficiency virus type 1 protease inhibitors.
复制标题
人类免疫缺陷病毒 1 型蛋白酶抑制剂。
DOI：
--
复制
发表时间：
1997
影响因子：
--
通讯作者：
D. Kuritzkes
中科院分区：
文献类型：
--
作者：
C. K. McDonald;D. Kuritzkes
Until recently, treatment for human immunodeficiency virus type 1 (HIV-1) infection was limited to the use of nucleoside inhibitors of the viral enzyme reverse transcriptase. While these agents initially offered promise, they have only modest antiviral activity and the benefits of treatment are limited by the emergence of drug resistance and dose-limiting toxic effects. Development of more potent drugs that target different stages of the virus life cycle has thus been aggressively pursued. Efforts to develop inhibitors of HIV-1 protease have yielded a potent new class of compounds that suppress HIV-1 replication to an extent far greater than was previously attainable. Four protease inhibitors, saquinavir mesylate, ritonavir, nelfinavir, and indinavir sulfate, have been approved by the Food and Drug Administration. Other agents are undergoing active investigation. The purpose of this article is to review the currently available data on those agents that have been approved for clinical use.
登录
查看更多内容
DOI：
10.1073/pnas.86.15.5781
发表时间：
1989-08-01
影响因子：
11.1
作者：
GOTTLINGER, HG;SODROSKI, JG;HASELTINE, WA
通讯作者：
HASELTINE, WA
影响因子：
158.5
作者：
Collier, AC;Coombs, RW;Corey, L
通讯作者：
Corey, L
影响因子：
56.9
作者：
ERICKSON, J;NEIDHART, DJ;KNIGGE, M
通讯作者：
KNIGGE, M
影响因子：
158.5
作者：
NESS, RB;HARRIS, T;DAGOSTINO, RB
通讯作者：
DAGOSTINO, RB
DOI：
10.1056/nejm199512073332204
发表时间：
1995-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
M. Markowitz;M. Saag;W. Powderly;A. Hurley;A. Hsu;J. Valdes;D. Henry;F. Sattler;Anthony F. La Marca;J. Leonard;D. Ho
通讯作者：
M. Markowitz;M. Saag;W. Powderly;A. Hurley;A. Hsu;J. Valdes;D. Henry;F. Sattler;Anthony F. La Marca;J. Leonard;D. Ho